Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 3, 1997, Pages 210-216

  Konstantinov, Spiro M ^a   Eibl, Hansjörg ^b   Berger, Martin R ^c  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Alkylphosphocholines; Apoptosis; HL 60 cells; K 562 cells; U 937 cells

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLINE DERIVATIVE; PHOSPHOLIPID DERIVATIVE; PHOSPHORYLCHOLINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHROMATIN CONDENSATION; CYTOTOXICITY; DRUG EFFECT; DRUG USE; HUMAN; HUMAN CELL; LEUKEMIA; PRIORITY JOURNAL;

EID: 0031904988     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050730     Document Type: Article

References (34)

1. Becher R, Kloke O, Füger A, Bremer K, Drozd A, Kleeberg UR, Fritze D, Rieche K, Sindermann H (1993) Phase II trial of orally administered Miltefosine in advanced colorectal cancer. Onkologie 16: 11
2. Berger MR, Eibl H (1992) Erucyphosphocholine is a second generation alkylphosphocholine (APC). 83rd Annual meeting of the American Association of Cancer Research. San Diego, 20-23 May 1992. Proc Am Assoc Cancer Res 33: 416
3. Berger MR, Muschiol C, Schmähl D, Eibl H (1987) New cytostatics with experimentally different toxic profiles. Cancer Treat Rev 14: 307
4. Brachwitz H, Vollgraf C (1995) Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol Ther 66: 39
5. Diomede L, Colotta F, Piovani B, Re F, Modest EJ, Salmona M (1993) Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine. A possible basis for its selective action. Int J Cancer 53: 124
6. Diomede L, Piovani B, Re F, Principe P, Colotta F, Modest EJ (1994) The induction of apoptosis is a common feature of ether-linked glycerophospholipids in human leukemic cells. Int J Cancer 57: 645
7. Dou QP, An B, Will PL (1995) Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc Natl Acad Sci USA 92: 9019
8. Eibl H, Engel J (1992) Synthesis of hexadecylphosphocholine (Miltefosine). In: Eibl H, Hilgard P, Unger C (eds) Progress in experimental tumor research, vol 34. New drugs in cancer therapy. Karger, Basel, pp 1-5
9. Eibl H, Hilgard P, Unger C (eds) (1992) Alkylphosphocholines: new drugs in cancer therapy. Prog Exp Tumor Res 34
10. Gangemi RM, Tiso M, Marchetti C, Severi AB, Fabbi M (1995) Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol 36: 385
11. Geilen CC, Haase R, Buchner K, Wieder T, Hucho F, Reutter W (1991) The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferation. Eur J Cancer 27: 1650
12. Geilen CC, Wieder T, Reutter W (1991) Hexadecylphosphocholine inhibits translocation of CTP: choline-phosphate cytidyltransferase in Madin-Darby canine kidney cells. J Biol Chem 267: 6719
13. Geilen CC, Haase A, Wieder T, Arndt D, Zeisig R, Reutter W (1994) Phospholipid analogues: side chain- and polar head-dependent effects on phosphatidylcholine biosynthesis. J Lipid Res 35: 625
14. Goppelt-Struebe M, Winter I (1995) Effects of hexadecylphosphocholine on fatty acid metabolism: relation to cytotoxicity. Cancer Chemother Pharmacol 35: 519
15. Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl H, Unger C, Berger MR (1988) Characterisation of antitumor activity of hexadecylphosphocholine (D 18506). Eur J Cancer Clin Oncol 24: 1457
16. Houlihan WJ, Lohmeyer M, Workman P, Cheon SH (1995) Phospholipid antitumor agents. Med Res Rev 15: 157
17. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S (1994) Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 54: 1707
18. Kaufmann-Kolle P, Drevs J, Berger MR, Kötting J, Marschner N, Unger C Eibl H (1994) Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother Pharmacol 34: 393
19. Kötting J, Berger MR, Unger C, Eibl H (1992) Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations. Cancer Chemother Pharmacol 30: 105
20. Martin S, Lennon S, Bonham A, Cotter TG (1990) Induction of apoptosis (programmed cell death) in human leukemic cells, by inhibitors of RNA protein synthesis. J Immunol 145: 1859
21. Maurer HR, Hilgard P (1992) Induction of tumor cell differentiation by alkylphosphocholines: a new approach for in vitro screening. Prog Exp Tumor Res 34: 90
22. McGahon A, et al (1994) BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83: 1179
23. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55
24. Planting AST, Stoter G, Verwij J (1993) Phase II study of daily oral Miltefosine (hexadecylphosphocholine) in advanced coloreclal cancer. Eur J Cancer 29A: 518
25. Sobotka SB, Berger MR, Eibl H (1993) Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo. Int J Cancer 53: 418
26. Spiess E, Brüning A, Gack S, Ulbricht B, Spring H, Günter T, Ebert W (1994) Cathepsin B activity in human lung tumor cell lines: ultrastructural localization, pH sensitivity, and inhibitor status at the cellular level. J Histochem Cytochem 42: 917
27. Stekar J, Hilgard P, Voegeli R, Maurer HR, Engel J, Kutscher B, Nößner G, Schumacher W (1993) Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid. D-20133. Cancer Chemother Pharmacol 32: 437
28. Unger C, Sindermann H, Peukert M, Hilgard P, Engel J, Eibl H (1992) Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer. Prog Exp Tumor Res 34: 153
29. Unger C, Becher R, Rieche K, Wandler HE, Friedlich G, Edler L (1993) Daily oral Miltefosine (hexadecylphosphocholine) in patients with advanced breast cancer: a phase II study. Onkologie 16: 260
30. Vehmayer K, Eibl H, Unger C (1992) Hexadecylphosphocholine stimulates the colony-stimulating factor-dependent growth of haematopoietic progenitor cells. Exp Hematol 20: 1
31. Venables WN, Ripley BD (1994) Modern applied statistics with S-Plus. Springer, Berlin, p 223
32. Verweji J (1996) New promising anticancer agents in development: what comes next? Cancer Chemother Pharmacol 38 [Suppl]: S3
33. Walker PR, Pandey S, Sikorska M (1995) Degradation of chromatin in apoptotic cells. Cell Death Differ 2: 97
34. Zhang W, McClain C, Gau J, Quo XD, Deisseroth AB (1994) Hyperphosphorylation of p53 induced by okadaic acid attenuates its transcriptional activation function. Cancer Res 54: 4448